Clinical trial · Observational
Application of Radiomics in Precise Preoperative Diagnosis and Prognsis Evaluation of Colorectal Cancer.
Application of Radiomics in Precise Preoperative Diagnosis and Prognsis Evaluation of Colorectal Cancer: a Prospective, Clinical Study
NCT03787667CI-TRIAL-00036270unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, clinical study. This study is to collect and analyze data of radiomics of primary site or metastasis of colorectal cancer aiming to precisizing preoperative diagnosis and long-term prognsis evaluation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Stage I-IV | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT or MRI based Radiomics | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with pathologically diagnosed colorectal cancer
- description
- Patients with pathologically diagnosed colorectal cancer
- interventionNames
- Diagnostic Test: CT or MRI based Radiomics
Primary outcomes (1)
- measure
- Sensitivity
- timeFrame
- 2 years
- description
- The sensitivity of radiomics in predicting regional or distant synchronous colorectal metastasis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with pathologically confirmed colorectal cancer * Male or female aged 18-75 years old on the day of signing informed consent. * Patients who received imageological examination of primary or metastasis * Patients who received surgical resection of primary or metastasis * Patients must have a performance status of ≤1 on the ECOG Performance Scale. * Colorectal cancer is the only malignant tumor * Written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study Exclusion Criteria: * Patients received adjuvant treatment prior to imageological examination * Tis stage patients * Paitents who diagnosed with malignant disease within 5 years. * Patients with a history or current evidence of any condition or abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the Investigator.
References
Publications (0)
Data not yet available
No reference posted for this study.